# v4.17

## Related releases

## Data changes

### Gene

```
MLH1 Gene Background Updated
```

### Alteration

```
APC Background Updated
ATM Background Updated
BAP1 Background Updated
BARD1 Background Updated
BRCA1 L51P Added
BRCA1 Background Updated
BRCA1 A5V Added
BRCA2 H2440R Added
BRCA2 Background Updated
BRCA2 T2310N Added
BRCA2 S445Y Added
BRIP1 Background Updated
CDH1 Background Updated
CHEK2 Background Updated
DDB2 Background Updated
DDB2 Truncating Mutations Added
DDB2 R273H Added
DDB2 K244E Added
DDB2 Summary Updated
EPCAM Background Updated
FGF8 Background Updated
FGF8 Summary Updated
FGF8 Amplification Added
FGF9 Background Updated
FGF9 Summary Updated
FGF9 Amplification Added
FOLR1 Summary Updated
FOLR1 Amplification Added
GPC3 Background Updated
GPC3 Amplification Added
GPC3 Summary Updated
GREM1 Background Updated
MSH2 Background Updated
MSH3 Background Updated
MSH6 Background Updated
MTAP Summary Updated
MUTYH Background Updated
PALB2 Background Updated
PMS2 Background Updated
POLD1 Background Updated
POLD1 R1016H Added
POLD1 D402N
POLD1 R689W Added
POLD1 L632M Added
POLD1 E318K Added
POLD1 E245K Added
POLD1 304_533mis [Exonuclease domain missense mutations] Added
POLE Summary Updated
POLE Background Updated
POLE Y458H Added
POLE Y458C Added
POLE S461T Added
POLE S461P Added
POLE P436S Added
POLE P436H Added
POLE L424P Added
POLE F367L Added
POLE E978K Added
POLE E978G Added
POLE D368N Added
POLE D275V Added
POLE D275G Added
POLE D275A Added
POLE C810G Added
POLE A463V Added
POLE A463T Added
POLE A463D Added
POLE A288V Added
POLE S461L Added
POLE G6R Added
POLE K425R Added
POLE R47W Added
POLE G330R Added
POLE D435G Added
POLE R446Q Added
POLE V464A Added
POLE 268_471mis [Exonuclease domain missense mutations] Added
RAD51B Background Updated
RAD51C Background Updated
RAD51D Background Updated
RB1 Background Updated
RET Y791F, Oncogenicity Updated
	 New: Inconclusive
	 Old: Likely
RET Background Updated
STK11 Background Updated
TOP2A Background Updated
TOP2A Summary Updated
TP53 Background Updated
VHL Background Updated
```

### Evidence

```
ALK G1202R, Non-Small Cell Lung Cancer, Summary Updated
ALK G1202R, Non-Small Cell Lung Cancer, Lorlatinib Added
ALK G1202R, Non-Small Cell Lung Cancer, Crizotinib Added
ALK G1202R, Non-Small Cell Lung Cancer, Ceritinib Added
ALK L1196M, Non-Small Cell Lung Cancer, Summary Updated
ALK G1202R, Non-Small Cell Lung Cancer, Brigatinib Added
ALK L1196M, Non-Small Cell Lung Cancer, Lorlatinib Added
BRAF Kinase Domain Duplication, Mutation Effect, Description Updated
CEBPA Oncogenic Mutations, AML with Biallelic Mutations of CEBPA, Diagnostic Summary Updated
DDB2 Gene Type, Tumor Suppressor Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], G719, S768I, L861Q, 729_761ins [Exon 19 in-frame insertions], Non-Small Cell Lung Cancer, Patritumab Deruxtecan, Description Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Mobocertinib Deleted
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Summary Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Other Tumor Types, Summary Updated
EGFR A763_Y764insFQEA (Exon 20 in-frame insertion), Non-Small Cell Lung Cancer, Summary Updated
EGFR A763_Y764insFQEA (Exon 20 in-frame insertion), Other Solid Tumor Types, Summary Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Trastuzumab Deruxtecan, Description Updated
FGF8 Gene Type, Oncogene Updated
FGF9 Gene Type, Oncogene Updated
GPC3 Gene Type, Oncogene Updated
KRAS G12C, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus, Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Biliary Tract Name Changed
	 New: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Biliary Tract
	 Old: Hepatobiliary Cancer, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumor, Small Bowel Cancer, Tubular Adenoma of the Colon
KRAS G12C, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus, Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Hepatobiliary Cancer Name Changed
	 New: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Hepatobiliary Cancer
	 Old: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Biliary Tract
MTAP Deletion, All Solid Tumors Added
MTAP Deletion, All Solid Tumors, AMG 193, Description Updated
MTAP Deletion, All Solid Tumors, MRTX1719, Description Updated
MTAP Deletion, All Solid Tumors, AMG 193, FDA Level Updated
MTAP Deletion, All Solid Tumors, MRTX1719, FDA Level Updated
NTRK1 Fusions, All Solid Tumors, Repotrectinib, Description Updated
NTRK2 Fusions, All Solid Tumors, Repotrectinib, Description Updated
NTRK3 Fusions, All Solid Tumors, Repotrectinib, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Small Bowel Cancer Added
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Ipilimumab + Nivolumab, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Small Bowel Cancer, Nivolumab, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Small Bowel Cancer, Ipilimumab + Nivolumab, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Dostarlimab Added
POLD1 S478N, Mutation Effect, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Colorectal Cancer, Nivolumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Colorectal Cancer, Ipilimumab + Nivolumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Colorectal Cancer, Dostarlimab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Small Bowel Cancer, Pembrolizumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Small Bowel Cancer, Nivolumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Small Bowel Cancer, Ipilimumab + Nivolumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Small Bowel Cancer, Dostarlimab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Colorectal Cancer, Pembrolizumab, Description Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Colorectal Cancer, Pembrolizumab, Additional Information Updated
POLD1 304_533mis [Exonuclease domain missense mutations], Other Solid Tumor Types Added
POLE F367S, Mutation Effect, Description Updated
POLE V411L, Mutation Effect, Oncogenic Updated
POLE P286R, Mutation Effect, Oncogenic Updated
POLE P286H, Mutation Effect, Oncogenic Updated
POLE V411L, Mutation Effect, Description Updated
POLE P286R, Mutation Effect, Description Updated
POLE P286H, Mutation Effect, Description Updated
POLE L424I, Mutation Effect, Description Updated
POLE S297F, Mutation Effect, Description Updated
POLE P286S, Mutation Effect, Description Updated
POLE S459F, Mutation Effect, Description Updated
POLE A456P, Mutation Effect, Description Updated
POLE P286L, Mutation Effect, Description Updated
POLE S461T, Mutation Effect, Description Updated
POLE S461P, Mutation Effect, Description Updated
POLE P436S, Mutation Effect, Description Updated
POLE P436H, Mutation Effect, Description Updated
POLE L424P, Mutation Effect, Description Updated
POLE F367L, Mutation Effect, Description Updated
POLE E978G, Mutation Effect, Description Updated
POLE D368N, Mutation Effect, Description Updated
POLE D275V, Mutation Effect, Description Updated
POLE D275G, Mutation Effect, Description Updated
POLE D275A, Mutation Effect, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Colorectal Cancer, Nivolumab, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Colorectal Cancer, Ipilimumab + Nivolumab, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Colorectal Cancer, Dostarlimab, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Small Bowel Cancer, Nivolumab, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Small Bowel Cancer, Ipilimumab + Nivolumab, Description Updated
POLE 268_471mis [Exonuclease domain missense mutations], Other Solid Tumor Types, Summary Updated
TOP2A Gene Type, Oncogene Updated
TP53 R290H, Mutation Effect, Description Updated
TP53 R290H, Mutation Effect, Effect Updated
TP53 R290H, Mutation Effect, Oncogenic Updated
```
